NantKwest Stock Goes North, uniQure s HOPE-B Trial On Hold, EU Greenlights First COVID-19 Vaccine
NEW YORK CITY (dpa-AFX) - Today s Daily Dose brings you news about NantKwest s non-muscle invasive bladder cancer trial results and the company s proposed merger with privately-held ImmunityBio; Agios sale of oncology portfolio to Servier for $1.8 billion upfront; the clinical hold on uniQure s hemophilia B gene therapy program due to safety concerns; ChemoCentryx ACCOLADE trial results; and the first COVID-19 vaccine authorized in the EU.
Read on.
1. Agios Sells Oncology Portfolio for $1.8 Bln Upfront
Agios Pharmaceuticals Inc. (AGIO) is all set to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company, for up to $2.0 billion in cash.